Groundbreaking study reveals substance use accelerates brain ageing through distinct molecular pathways

Researchers have uncovered crucial evidence that substance use disorders (SUDs) accelerate biological ageing in the brain through distinct molecular mechanisms. The groundbreaking study examines how different substances, such as alcohol, opioids, and stimulants, affect the brain’s ageing process at the molecular level, potentially explaining why individuals with SUDs often experience early-onset age-related diseases.

The research team, analysed brain tissue from 58 donors with SUDs to assess differential ageing patterns using specialised epigenetic clocks designed specifically for brain tissues.

Unlike previous studies that relied on more general epigenetic ageing markers, this investigation employed brain-specific tools (DNAmClockCortical, CerebralCortexClockcommon, and PCBrainAge) to provide a more accurate assessment of neural ageing.

“Our study is the first to investigate brain accelerated ageing in substance use disorders using epigenetic clocks specifically designed for brain tissues,” explains Dr. Kluwe-Schiavon.

“This approach allowed us to capture unique aspects of the ageing process in the brain that might have been missed with more general methods.”

The researchers, led by Drs. Bruno Kluwe-Schiavon, Gabriel Fries, and Consuelo Walss-Bass, focused on the dorsolateral prefrontal cortex, a brain region central to decision-making and executive control that is particularly vulnerable to addiction. By examining postmortem brain tissue and conducting sophisticated gene expression analyses, the team identified specific molecular signatures associated with accelerated ageing in different SUDs.

One of the study’s most significant findings was that different substances appear to accelerate brain ageing through distinct biological pathways. In alcohol use disorder, researchers found altered expression of genes involved in protein phosphorylation, signal transduction, and glutamatergic synapse function. For opioid use disorder, transcriptional regulation, neurodevelopment, and immune-inflammatory processes emerged as key drivers of accelerated ageing.

Stimulant use disorder showed distinct patterns related to oxidative stress, hypoxia responses, and cell adhesion pathways.

Dr. Walss-Bass said: “We’ve discovered that accelerated ageing in substance use disorders is not a uniform process. Each substance appears to hijack the brain’s natural ageing rhythm through unique molecular mechanisms, though some pathways are shared across different substance types.”

Despite the differences between substances, the research identified some common biological mechanisms across all SUDs. Neuroinflammation, oxidative stress, and mitochondrial dysfunction appeared to play crucial roles in accelerated ageing regardless of the specific substance used.

“Our integrative analysis suggests that mitochondrial function, the powerhouse of the cell, is central to maintaining cellular energy homeostasis and regulating oxidative stress responses,” notes Dr. Gabriel Fries, co-corresponding author of the study.

“When substance use disrupts these processes, it can accelerate the biological ageing of neural tissue.”

The findings have profound implications for public health, addiction medicine, and treatment approaches. If substance use induces premature biological ageing, it should be viewed not merely as a behavioural choice but as an accelerant of neurodegeneration.

“What we call relapse may sometimes be the cognitive exhaustion of a prematurely aged cortex,” said Dr. Kluwe-Schiavon.

“This perspective shifts how we think about addiction treatment and recovery.”

The research opens the door to a new field that the authors describe as “the psychiatry of ageing in young people.” It calls for longitudinal investigations that follow individuals through abstinence, relapse, remission, and decay, as well as integrative biomarker panels that combine methylation, gene expression, and neuroimaging.

In his accompanying editorial, Dr. Julio Licinio offers a thought-provoking perspective on the study’s implications.

“This is not just a question of whether drugs kill. We already know they do. The deeper question, provocative and new, thanks to this anatomically grounded work, is whether drugs age the brain,” writes Dr. Licinio.

He emphasises that the ageing effects observed in substance use disorders are “neither cosmetic nor metaphorical. It is cellular. It is molecular. And it is coded into the methylated terrain of the genome.”

Dr. Licinio notes that the findings have implications far beyond the laboratory, reaching into public health, addiction medicine, criminal justice, and education policy.

“If substance use induces premature biological ageing, then we must treat it not merely as a moral lapse or behavioural choice, but as an accelerant of neurodegeneration,” he argues.

While the study provides valuable insights, the researchers acknowledge several limitations, including the relatively small sample size and cross-sectional design, which limits causal interpretations. They call for future research with larger cohorts and longitudinal designs to confirm their findings and further elucidate the mechanisms of accelerated ageing in different SUDs.

An intriguing question emerging from this research is why some brains deteriorate faster than others under similar pharmacological conditions. Could there be predisposing genomic signatures, either genetic susceptibilities or epigenetic scars left by early-life adversity, that make some individuals biologically more vulnerable to substance-induced ageing?

“If one is to be optimistic, and one must be, even in the face of molecular entropy, then perhaps these findings mark the beginning of a therapeutic redirection,” Dr. Licinio suggests in his editorial.

“Anti-ageing interventions, long the obsession of cosmetic medicine and Silicon Valley biohackers, might soon find their most ethically urgent application in addiction psychiatry.”